logo-loader
viewGT Biopharma Inc.

GT Biopharma unique technology targeting Lymphoma and Leukemia cell lines

GT Biopharma (OTCQB:GTBP) Dr. Raymond Urbanski sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.  The clinical stage biopharmaceutical company is focused on the development and commercialization of immuno-oncology products based off its proprietary Tri-specific Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate (ADC) technology platforms.

Quick facts: GT Biopharma Inc.

Price: 0.09 USD

OTCQB:GTBP
Market: OTCQB
Market Cap: $6.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Standard Uranium shares details of their project as they...

Standard Uranium (CVE: STND) President and CEO Jon Bey sat down with Steve Darling from Proactive Vancouver to discuss details about uranium exploration company that plan to take public very soon.  Bey telling Proactive about their project in the Athabasca Basin and also abut their...

17 minutes ago

2 min read